DelMar Pharmaceuticals Inc (DMPI)

6.71
0.19 2.80
NASDAQ : Health Care
Prev Close 6.90
Open 6.83
Day Low/High 6.58 / 6.85
52 Wk Low/High 1.72 / 10.87
Volume 22.75K
Avg Volume 30.40K
Exchange NASDAQ
Shares Outstanding 10.06M
Market Cap 70.95M
EPS -0.30
P/E Ratio 12.59
Div & Yield N.A. (N.A)

Latest News

Shares of DelMar End Lower on First Day of Trading

Shares of DelMar End Lower on First Day of Trading

DelMar Pharmaceuticals enjoyed a bit of good news this week after its shares were uplisted to the Nasdaq Capital Market this week.

DelMar Pharmaceuticals Announces Approval For Listing On NASDAQ

DelMar Pharmaceuticals Announces Approval For Listing On NASDAQ

DMPI to Begin Trading on NASDAQ Capital Market on July 12, 2016

DelMar Pharmaceuticals Announces Reverse Stock Split In Preparation For Proposed Senior Exchange Uplisting

DelMar Pharmaceuticals Announces Reverse Stock Split In Preparation For Proposed Senior Exchange Uplisting

- Company will host its quarterly business update conference call and webcast today at 5 PM EDT -

DelMar Pharmaceuticals, Inc. Announces $5.6 Million Private Placement Of Preferred Shares

DelMar Pharmaceuticals, Inc. Announces $5.6 Million Private Placement Of Preferred Shares

New funds and restructuring of warrants to eliminate a significant portion of derivative liability positions Company to meet senior exchange listing requirement

FDA Grants Orphan Drug Designation For VAL-083 In Ovarian Cancer

FDA Grants Orphan Drug Designation For VAL-083 In Ovarian Cancer

New Orphan Designation is the Third Awarded to DelMar Pharmaceuticals by FDA Office of Orphan Products Development (OOPD)

DelMar Pharmaceuticals Updates Ongoing Phase I/II Refractory GBM Clinical Trial With VAL-083 At American Association Cancer Research (AACR) Annual Meeting

DelMar Pharmaceuticals Updates Ongoing Phase I/II Refractory GBM Clinical Trial With VAL-083 At American Association Cancer Research (AACR) Annual Meeting

Results to date support the potential of VAL-083 as a new treatment paradigm for GBM patients who have failed or are unlikely to respond to currently available treatments

DelMar Pharmaceuticals Announces New Data Supporting The Unique Anti-cancer Mechanism Of VAL-083

DelMar Pharmaceuticals Announces New Data Supporting The Unique Anti-cancer Mechanism Of VAL-083

Unique mechanism of action takes advantage of tumor mutations; Findings provide direction for future combination therapies

DelMar's VAL-083 Demonstrates Promise In The Treatment Of Non-Small Cell Lung Cancer And Ovarian Cancer

DelMar's VAL-083 Demonstrates Promise In The Treatment Of Non-Small Cell Lung Cancer And Ovarian Cancer

MD Anderson Researchers Presented New Pre-clinical Data Today at the American Association of Cancer Research (AACR) Annual Meeting

DelMar Pharmaceuticals Announces Abstract Presentations For The American Association Cancer Research (AACR) Annual Meeting In April 2016

DelMar Pharmaceuticals Announces Abstract Presentations For The American Association Cancer Research (AACR) Annual Meeting In April 2016

Update on DelMar's Phase I/II Refractory GBM Clinical Trial with VAL-083 to be published as a late-breaking abstract on April 19, 2016

FDA Grants Second Orphan Designation For VAL-083

FDA Grants Second Orphan Designation For VAL-083

FDA Office of Orphan Products Development (OOPD) has granted orphan drug designation for VAL-083 in the treatment of medulloblastoma

DelMar Pharmaceuticals To Present At The 18th Annual BIO CEO & Investor Conference On February 8, 2016

DelMar Pharmaceuticals To Present At The 18th Annual BIO CEO & Investor Conference On February 8, 2016

- Presentation with live webcast on Monday, February 8th at 10:00 a.m. EST -

DelMar Pharmaceuticals To Collaborate With MD Anderson Cancer Center On Development Of DelMar's VAL-083 In Brain Cancer

DelMar Pharmaceuticals To Collaborate With MD Anderson Cancer Center On Development Of DelMar's VAL-083 In Brain Cancer

- MD Anderson to initiate new clinical studies for the treatment of recurrent GBM -

DelMar Pharmaceuticals To Present At The Biotech Showcase™ 2016 On January 12, 2016

DelMar Pharmaceuticals To Present At The Biotech Showcase™ 2016 On January 12, 2016

- Presentation with live webcast on Tuesday, January 12th at 11:00 a.m. PT -

DelMar Pharmaceuticals Updates VAL-083 Clinical Trial In Refractory Glioblastoma Multiforme At Society For Neuro-Oncology Annual Meeting

DelMar Pharmaceuticals Updates VAL-083 Clinical Trial In Refractory Glioblastoma Multiforme At Society For Neuro-Oncology Annual Meeting

- Interim Phase II data supports clinically meaningful survival benefit in post bevacizumab refractory GBM -

DelMar Pharmaceuticals To Present At The 8th Annual LD Micro Main Event On December 2, 2015

DelMar Pharmaceuticals To Present At The 8th Annual LD Micro Main Event On December 2, 2015

- Presentation with live webcast on Wednesday, December 2nd at 3:30 p.m. PT -

DelMar Pharmaceuticals Presents Data Summarizing The Potential Of VAL-083 As A New Treatment Option For Resistant Cancers

DelMar Pharmaceuticals Presents Data Summarizing The Potential Of VAL-083 As A New Treatment Option For Resistant Cancers

- VAL-083 offers a promising solution for major unmet needs in the treatment of a variety of cancers -

DelMar Pharmaceuticals Presents Data Supporting VAL-083 As A Promising Potential Treatment For Pediatric Brain Tumors

DelMar Pharmaceuticals Presents Data Supporting VAL-083 As A Promising Potential Treatment For Pediatric Brain Tumors

- Preclinical and clinical data support advancement of VAL-083 into a clinical study in pediatric patients with recurrent or resistant medulloblastoma (MB) and high grade gliomas (HGGs) -

DelMar Pharmaceuticals Collaborators Present Data On The Unique Molecular Mechanisms Responsible For VAL-083 Activity Against Cancer

DelMar Pharmaceuticals Collaborators Present Data On The Unique Molecular Mechanisms Responsible For VAL-083 Activity Against Cancer

- Third-party data further validate differentiation of VAL-083 vs. other chemotherapeutic agents -

DelMar Pharmaceuticals To Present Updated Phase II Safety And Efficacy Data On VAL-083 In Refractory Glioblastoma Multiforme

DelMar Pharmaceuticals To Present Updated Phase II Safety And Efficacy Data On VAL-083 In Refractory Glioblastoma Multiforme

- Data to be presented at the 20th Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology -

DelMar Pharmaceuticals To Present At The SeeThruEquity Microcap Investor Forum On November 12, 2015

DelMar Pharmaceuticals To Present At The SeeThruEquity Microcap Investor Forum On November 12, 2015

- Presentation with live webcast on Thursday, November 12th at 10:00 a.m. ET -

DelMar Pharmaceuticals Announces The Completion Of Enrollment In Its Phase II Expansion Study Of VAL-083 In Refractory Glioblastoma Multiforme

DelMar Pharmaceuticals Announces The Completion Of Enrollment In Its Phase II Expansion Study Of VAL-083 In Refractory Glioblastoma Multiforme

- Company confirms 40mg/square meter as the maximum tolerated dose (MTD) for advancement into registration-directed clinical trials -

DelMar Pharmaceuticals Presents Positive Preclinical Data On VAL-083 As A Promising Treatment For Ovarian Cancer

DelMar Pharmaceuticals Presents Positive Preclinical Data On VAL-083 As A Promising Treatment For Ovarian Cancer

- Data support VAL-083 as a viable treatment option for patients failing platinum-based chemotherapy -

DelMar Pharmaceuticals To Present At The 14th Annual BIO Investor Forum

DelMar Pharmaceuticals To Present At The 14th Annual BIO Investor Forum

- Presentation with live webcast on October 21, 2015 at 3:00 p.m. PDT -

DelMar Pharmaceuticals To Present Data On The Promising Potential Of VAL-083 In The Treatment Of Pediatric Brain Tumors

DelMar Pharmaceuticals To Present Data On The Promising Potential Of VAL-083 In The Treatment Of Pediatric Brain Tumors

- Abstract to be presented at AACR Advances in Pediatric Cancer Research: From Mechanisms and Models to Treatment and Survivorship Conference -